New options for the management of chronic hyperkalemia

Linda Fried, Csaba P. Kovesdy, Biff F. Palmer

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Hyperkalemia is a frequently detected electrolyte abnormality that can cause life-threatening complications. Hyperkalemia is most often the result of intrinsic (decreased glomerular filtration rate; selective reduction in distal tubule secretory function; impaired mineralocorticoid activity; and metabolic disturbances, such as acidemia and hyperglycemia) and extrinsic factors (e.g., drugs, such as renin-angiotensin-aldosterone system inhibitors, and potassium intake). The frequent use of renin-angiotensin-aldosterone system inhibitors in patients who are already susceptible to hyperkalemia (e.g., patients with chronic kidney disease, diabetes mellitus, or congestive heart failure) contributes to the high incidence of hyperkalemia. There is a need to understand the causes of hyperkalemia and to be aware of strategies addressing the disorder in a way that provides the most optimal outcome for affected patients. The recent development of 2 new oral potassium-binding agents has led to the emergence of a new paradigm in the treatment of hyperkalemia.

Original languageEnglish (US)
Pages (from-to)164-170
Number of pages7
JournalKidney International Supplements
Volume7
Issue number3
DOIs
StatePublished - Dec 1 2017

Fingerprint

Hyperkalemia
Renin-Angiotensin System
Potassium
Mineralocorticoids
Glomerular Filtration Rate
Chronic Renal Insufficiency
Hyperglycemia
Electrolytes
Diabetes Mellitus
Heart Failure
Incidence
Pharmaceutical Preparations

Keywords

  • chronic kidney disease
  • hyperkalemia
  • potassium
  • treatment

ASJC Scopus subject areas

  • Nephrology

Cite this

New options for the management of chronic hyperkalemia. / Fried, Linda; Kovesdy, Csaba P.; Palmer, Biff F.

In: Kidney International Supplements, Vol. 7, No. 3, 01.12.2017, p. 164-170.

Research output: Contribution to journalReview article

Fried, Linda ; Kovesdy, Csaba P. ; Palmer, Biff F. / New options for the management of chronic hyperkalemia. In: Kidney International Supplements. 2017 ; Vol. 7, No. 3. pp. 164-170.
@article{2fd6a0971bb34e99aa6e1ff5802cba59,
title = "New options for the management of chronic hyperkalemia",
abstract = "Hyperkalemia is a frequently detected electrolyte abnormality that can cause life-threatening complications. Hyperkalemia is most often the result of intrinsic (decreased glomerular filtration rate; selective reduction in distal tubule secretory function; impaired mineralocorticoid activity; and metabolic disturbances, such as acidemia and hyperglycemia) and extrinsic factors (e.g., drugs, such as renin-angiotensin-aldosterone system inhibitors, and potassium intake). The frequent use of renin-angiotensin-aldosterone system inhibitors in patients who are already susceptible to hyperkalemia (e.g., patients with chronic kidney disease, diabetes mellitus, or congestive heart failure) contributes to the high incidence of hyperkalemia. There is a need to understand the causes of hyperkalemia and to be aware of strategies addressing the disorder in a way that provides the most optimal outcome for affected patients. The recent development of 2 new oral potassium-binding agents has led to the emergence of a new paradigm in the treatment of hyperkalemia.",
keywords = "chronic kidney disease, hyperkalemia, potassium, treatment",
author = "Linda Fried and Kovesdy, {Csaba P.} and Palmer, {Biff F.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/j.kisu.2017.09.001",
language = "English (US)",
volume = "7",
pages = "164--170",
journal = "Kidney International Supplements",
issn = "2157-1724",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - New options for the management of chronic hyperkalemia

AU - Fried, Linda

AU - Kovesdy, Csaba P.

AU - Palmer, Biff F.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Hyperkalemia is a frequently detected electrolyte abnormality that can cause life-threatening complications. Hyperkalemia is most often the result of intrinsic (decreased glomerular filtration rate; selective reduction in distal tubule secretory function; impaired mineralocorticoid activity; and metabolic disturbances, such as acidemia and hyperglycemia) and extrinsic factors (e.g., drugs, such as renin-angiotensin-aldosterone system inhibitors, and potassium intake). The frequent use of renin-angiotensin-aldosterone system inhibitors in patients who are already susceptible to hyperkalemia (e.g., patients with chronic kidney disease, diabetes mellitus, or congestive heart failure) contributes to the high incidence of hyperkalemia. There is a need to understand the causes of hyperkalemia and to be aware of strategies addressing the disorder in a way that provides the most optimal outcome for affected patients. The recent development of 2 new oral potassium-binding agents has led to the emergence of a new paradigm in the treatment of hyperkalemia.

AB - Hyperkalemia is a frequently detected electrolyte abnormality that can cause life-threatening complications. Hyperkalemia is most often the result of intrinsic (decreased glomerular filtration rate; selective reduction in distal tubule secretory function; impaired mineralocorticoid activity; and metabolic disturbances, such as acidemia and hyperglycemia) and extrinsic factors (e.g., drugs, such as renin-angiotensin-aldosterone system inhibitors, and potassium intake). The frequent use of renin-angiotensin-aldosterone system inhibitors in patients who are already susceptible to hyperkalemia (e.g., patients with chronic kidney disease, diabetes mellitus, or congestive heart failure) contributes to the high incidence of hyperkalemia. There is a need to understand the causes of hyperkalemia and to be aware of strategies addressing the disorder in a way that provides the most optimal outcome for affected patients. The recent development of 2 new oral potassium-binding agents has led to the emergence of a new paradigm in the treatment of hyperkalemia.

KW - chronic kidney disease

KW - hyperkalemia

KW - potassium

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85035785574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035785574&partnerID=8YFLogxK

U2 - 10.1016/j.kisu.2017.09.001

DO - 10.1016/j.kisu.2017.09.001

M3 - Review article

C2 - 30675431

AN - SCOPUS:85035785574

VL - 7

SP - 164

EP - 170

JO - Kidney International Supplements

JF - Kidney International Supplements

SN - 2157-1724

IS - 3

ER -